Effector

eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Retrieved on: 
Monday, February 5, 2024

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that Steve Worland, Ph.D., president, and chief executive officer of eFFECTOR, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14th at 10:40 am ET.

Key Points: 
  • SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that Steve Worland, Ph.D., president, and chief executive officer of eFFECTOR, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14th at 10:40 am ET.
  • A live webcast of the virtual presentations will be available on the "Events and Presentations" page of the Investors section of the Company’s website with a replay available for 90 days following the event.
  • For more information, please visit investors.effector.com .

eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024

Retrieved on: 
Tuesday, January 9, 2024

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that it will host a virtual investor R&D Day on Wednesday, January 24, 2024, at 4:30 pm ET.

Key Points: 
  • -  Webinar to take place on Wednesday, January 24, 2024, at 4:30 pm ET-
    SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that it will host a virtual investor R&D Day on Wednesday, January 24, 2024, at 4:30 pm ET.
  • The eFFECTOR Investor R&D Day will feature the management team and include a presentation by Kevin Kalinsky, MD, MS, professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine and Director of the Glenn Family Breast Center at the Winship Cancer Institute.
  • Steve Worland, Ph.D., president and chief executive officer of eFFECTOR said: “We are pleased with the development progress of both of our wholly-owned Phase 2 drug candidates.
  • We look forward to showcasing both of our tomivosertib and zotatifin programs at our Investor R&D Day and are excited to have Dr. Kalinsky share his insights.”
    The presentations will be followed by a live Q&A session.

eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients

Retrieved on: 
Friday, December 8, 2023

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Dec. 08, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced new positive interim data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 clinical study of zotatifin in patients with estrogen receptor positive (ER+) metastatic breast cancer (mBC). The data, reflecting a cutoff date of Nov. 17, 2023, is being presented by Ezra Rosen, M.D., Ph.D., Medical Oncologist and Early Drug Development Specialist, Memorial Sloan Kettering Cancer Center, at the 2023 San Antonio Breast Cancer Symposium (SABCS®), held from December 5 – 9, 2023 in San Antonio, Texas.

Key Points: 
  • As previously reported, five of 19 (26%) RECIST-evaluable patients had partial responses, including four confirmed and one unconfirmed.
  • In the new ZF dose escalation cohorts, three patients were enrolled at each dose level of 0.1, 0.14 and 0.2 mg/kg zotatifin administered once every two weeks, combined with fulvestrant.
  • The patients were heavily pretreated, with a median of four prior lines of treatment for metastatic disease.
  • The company expects to report additional data from dose escalation in the first half of 2024.

eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer

Retrieved on: 
Tuesday, November 28, 2023

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for zotatifin in combination with fulvestrant and abemaciclib (ZFA triplet) as second- or third-line therapy for the treatment of adult patients with estrogen receptor-positive (ER+)/human epidermal growth factor-negative (HER2-) advanced or metastatic breast cancer with disease progression following treatment with endocrine therapy and a CDK 4/6 inhibitor. The Fast Track designation was granted following FDA review of preclinical and clinical data for zotatifin, including recent safety and efficacy data for the ZFA triplet.

Key Points: 
  • The Fast Track designation was granted following FDA review of preclinical and clinical data for zotatifin, including recent safety and efficacy data for the ZFA triplet.
  • "We’re grateful to receive this Fast Track designation from FDA, which is a meaningful milestone for the development of zotatifin and reflects the demonstrated potential for zotatifin in combination with fulvestrant and abemaciclib to address unmet needs in ER+/HER2- breast cancer,” said Steve Worland, Ph.D., chief executive officer of eFFECTOR.
  • Zotatifin is being investigated in a Phase 1/2 dose escalation and expansion study, with cohorts currently enrolling in ER+/HER2- breast cancer.
  • Based on safety and tolerability results to date, dose escalation was resumed in combination with fulvestrant (ZF doublet).

eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  • These results, if positive, would enable activities, including interactions with regulatory agencies, intended to support initiation of a Phase 3 registrational trial.
  • Research and Development (R&D) Expenses: R&D expenses were $5.4 million for the quarter ended September 30, 2023, compared to $6.6 million for the same quarter of 2022.
  • Other Income (Expense): Other expense was $0.4 million for the quarter ended September 30, 2023, compared to $0.3 million for the same quarter of 2022.

eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference

Retrieved on: 
Monday, November 6, 2023

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will participate in a fireside chat discussion and host 1x1 meetings at the 2023 Stifel Healthcare Conference taking place November 14-15, 2023 in New York, NY.

Key Points: 
  • SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will participate in a fireside chat discussion and host 1x1 meetings at the 2023 Stifel Healthcare Conference taking place November 14-15, 2023 in New York, NY.
  • Steve Worland, Ph.D., president and chief executive officer of eFFECTOR, will participate in a fireside chat discussion of the Company’s clinical development pipeline and corporate strategy to be held on Wednesday, November 15 at 12:40 PM ET.
  • A live webcast of the event will be available on the "Events and Presentations" page of the Investors section of the Company’s website with a replay available for 90 days following the event.
  • For more information, please visit investors.effector.com.

eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia

Retrieved on: 
Tuesday, October 24, 2023

The trial will be conducted at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and chaired by Shira Dinner, M.D., Associate Professor of Medicine (Hematology and Oncology).

Key Points: 
  • The trial will be conducted at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and chaired by Shira Dinner, M.D., Associate Professor of Medicine (Hematology and Oncology).
  • Tomivosertib is an inhibitor of mitogen-activator protein kinase interacting kinase (MNK) 1 and 2 and blocks phosphorylation of eukaryotic initiation factor 4E (eIF4E).
  • “AML is one of the most common types of acute leukemia, and unfortunately, development of resistance to existing therapies leads to relapse in too many patients,” said Dr. Platanias.
  • “Additionally, for older and high-risk younger adult patients who cannot tolerate intensive chemotherapy, there are few treatment options.

eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors

Retrieved on: 
Monday, September 11, 2023

Concurrent with Ms. Loewy’s appointment, current Board member John Smither has resigned from the Board.

Key Points: 
  • Concurrent with Ms. Loewy’s appointment, current Board member John Smither has resigned from the Board.
  • “We are tremendously fortunate to welcome Caroline given her extensive experience as an executive and board member at multiple biopharmaceutical companies,” remarked Steve Worland, Ph.D., president and chief executive officer of eFFECTOR.
  • At the same time, on behalf of the entire eFFECTOR team and the Board, I would like to express our utmost gratitude to John for his invaluable contributions to eFFECTOR.”
    “I look forward to working with the management team and other Board members at eFFECTOR,” said Ms. Loewy.
  • Ms. Loewy also currently sits on the board of CymaBay Therapeutics, Inc., PhaseBio Pharmaceuticals, Inc. and Phoenix Biotech Acquisition Corp. Ms. Loewy holds a B.A.

eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 8, 2023

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • “It was another productive quarter for eFFECTOR as we made considerable progress on all fronts,” remarked Steve Worland, Ph.D., president and chief executive officer of eFFECTOR.
  • Topline data are anticipated in the second half of 2023.
  • $16.2 million in gross proceeds raised from two registered direct financings, extending cash runway into second quarter of 2024. eFFECTOR completed two registered direct financings during the second quarter of 2023.
  • eFFECTOR anticipates that its current cash, cash equivalents and short-term investments will be sufficient to fund operations into the second quarter of 2024.

eFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting

Retrieved on: 
Thursday, May 25, 2023

SOLANA BEACH and REDWOOD CITY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced positive interim data updates from a Phase 2 expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib (ZFA triplet) in patients with ER+ metastatic breast cancer (mBC). These data, as well as initial data from further dose escalation, will be presented as a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6 in Chicago, IL by Ezra Rosen, M.D. from Memorial Sloan Kettering Cancer Center (MSK). The Company will host a virtual investor call on Sunday, June 4, 2023, at 6:30 PM CT / 7:30 PM ET to discuss the data and clinical progress. Sarat Chandarlapaty, M.D., Ph.D. of MSK will join the call to discuss the unmet medical need and current treatment landscape for patients with ER+ mBC.

Key Points: 
  • New interim data were presented on the fully enrolled expansion cohort of patients (n=20) who received the ZFA triplet with zotatifin dosed at 0.07 mg/kg on Days 1 and 8 of 21-day cycles.
  • Patients were heavily pre-treated, having received a median of four prior lines of therapy for metastatic disease.
  • Five out of 19 (26%) RECIST-evaluable patients achieved a partial response (PR), including four confirmed and one unconfirmed.
  • Zotatifin has been generally well tolerated in dose escalation cohorts, with no dose limiting toxicities or serious adverse events observed.